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With  the  availability  of  the nonavalent  human  papillomavirus  (HPV)  vaccine,  vaccinees,  parents  and
healthcare  providers  need  guidance  on  how  to  complete  an  immunization  course started  with  the  bi-  or
quadrivalent  vaccine  and  whether  to revaccinate  individuals  who  have  completed  a full  immunization
course  with  the  bi- or quadrivalent  vaccine.  To  answer  these  questions  three  parameters  should  be con-ccepted 23 December 2015
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sidered:  age  at the  start  of  vaccination  (9 to  14 years  of  age  versus  15  years  and  older,  the  cut-off  for  2
or  3 doses  schedule),  the  number  of  doses  already  received  and  the  time  interval  between  doses.  Based
on  a  number  of  scenarios,  we  propose  that  the  9-valent  vaccine  can  be  used  to  complete  an  incomplete
vaccination  regimen  or might  be  added  to a  previous  completed  schedule  to extend  protection.
© 2016  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).The new nonavalent HPV vaccine (9vHPV, trade name Gardasil9)
as been approved for use in USA [1], Canada [2], Australia [3], and
he European Union [4]. This vaccine includes high-risk HPV types
6, 18, 31, 33, 45, 52, and 58 in addition to the low-risk HPV types
 and 11.
This new vaccine comes in addition to two HPV vaccines already
ommercially available in a large number of countries. Cervarix® is
 bivalent vaccine (2vHPV) that targets HPV16 and 18, two  HPV
ypes that cause cervical cancer. Gardasil® (4vHPV) targets the
ame oncogenic types, as well as HPV6 and 11, which cause external
enital warts. Thus far, millions of women and a smaller number
f men  have been immunized with these two HPV vaccines, with a
ell-documented safety proﬁle [5–9]. Both vaccines protect against
PV type 16/18 related genital diseases, essentially against 50% of
∗ Corresponding author. Tel.: +32 32652538; fax: +32 32652640.
E-mail address: pierre.vandamme@uantwerp.be (P. Van Damme).
ttp://dx.doi.org/10.1016/j.vaccine.2015.12.063
264-410X/© 2016 The Authors. Published by Elsevier Ltd. This is an open access article 
/).cervical intraepithelial neoplasia (CIN) 2/3 and 70% of cervical can-
cer [10]. The 5 additional types in 9vHPV increase the protection
against cervical cancer to approximately 90%. For CIN1, CIN2 and
CIN3 lesions, the increases are 20%, 30% and 30%, respectively [11],
see Fig. 1.
With the availability of the 9vHPV, vaccinees (and their par-
ents) and healthcare providers may  wonder how to complete an
immunization course started with the bi- or quadrivalent vaccine
and whether to revaccinate individuals who have completed a full
immunization course with the bi- or quadrivalent vaccine. The
European summary of product characteristics of the three HPV
vaccines states that individuals who received a ﬁrst dose with a
given HPV vaccine should complete the vaccination course with
that same vaccine [12–14]. The US Advisory Committee on Immu-
nization Practices (ACIP) [15,16] on the other hand, states that “any
available HPV vaccine product may  be used to continue or complete
the series for females for protection against HPV 16 and 18”. Tak-
ing the above into consideration, we  propose a pragmatic approach
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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sig. 1. Contribution of high risk HPV types covered by the bi- and quadrivalent va
vHPV  types are: 6, 11, 16, 18, 31, 33, 45, 52, and 58. The overall contribution of H
artwig et al. [11].
ased on limited existing data, and where data are not yet available,
n expert opinion. The proposed guidelines are drafted for a tran-
itional period, and address the questions raised on an individual
ather than on a programmatic level. While drafting the different
cenarios we did not take economic considerations into account,
s the proposed schedules have not been sufﬁciently evaluated
conomically [15,16].
A pivotal randomized, controlled clinical trial (RCT) [17] com-
aring 9vHPV with the 4vHPV vaccine demonstrated a high vaccine
fﬁcacy of 9vHPV against high-grade cervical, vulvar, or vaginal
isease related to the new HPV types 31, 33, 45, 52, and 58 of
6.7% (95% conﬁdence interval, 80.9% to 99.8%). Simultaneously,
ntibody responses to HPV-6, 11, 16, and 18 were non-inferior to
hose generated by the 4vHPV vaccine. Consequently, efﬁcacy for
vHPV against persistent infection and disease related to HPV types
, 11, 16, or 18 can be inferred to be comparable to that of 4vHPV
17]. Finally, immunization with 9vHPV was shown to be well tol-
rated and safe in the pivotal RCT, and although it resulted in more
dverse local reactions than vaccination with the 4vHPV vaccine, as
xpected due to the higher dose of antigen and/or adjuvant, more
han 90% of these reactions were mild to moderate in intensity [17].
Subsequent injection (using 9vHPV to complete a HPV vacci-
ation course initiated with a bi- or quadrivalent vaccine) has
ot been assessed in the clinical development program so far.
imilarly, no data are available on revaccination with 9vHPV of
ubjects who completed an immunization course with 2vHPV.
Fig. 2. Geometric mean titers in 4vHPV naïve and 4vHPV-vaccinated ws and the nonavalent vaccine to cervical cancer and precancerous cervical lesions.
 CIN 1 = 73%, CIN 2 = 86%, CIN 3 = 93%, cervical cancer = 100%. Figure adapted from
Revaccination was investigated in a clinical trial (study V503-006,
ClinicalTrials.gov Identiﬁer: NCT01047345), which assessed the
safety and immunogenicity of complete 3 doses 9vHPV adminis-
tration in 4vHPV recipients (3-dose schedule) with a minimum
12-month interval (with the third dose of 4vHPV administered
at least one year prior to the ﬁrst dose of 9vHPV) [18]. 9vHPV
was found to be highly immunogenic without safety concerns.
In the group that received 3 doses of 4vHPV and then 3 doses
of 9vHPV, the geometric mean titers (GMTs) to HPV types 6, 11,
16, 18 were higher than in the 4vHPV vaccine naïve population
from other studies, whereas the GMTs to HPV Types 31, 33, 45,
52 and 58 were lower than in 9vHPV-vaccinated, 4vHPV vaccine
naïve subjects, see Fig. 2 [18]. The expectation is that these girls
will be protected against the 5 new HPV types. Whether protec-
tion is comparable to that against HPV types 6, 11, 16, 18 is yet
unknown.
To answer the two questions on how to complete an immuniza-
tion course started with the bi- or quadrivalent vaccine and the
usefulness of revaccinating individuals who have completed a full
immunization course with the bi- or quadrivalent vaccine, three
parameters should be considered: age (9 to 14 years of age versus
15 years and older, the cut-off for 2 or 3 doses schedule), the num-
ber of doses already received and the time interval between doses.
For those countries considering male vaccination, our recommen-
dations for girls are also valid for boys, as immunogenicity in boys
is similar, if not higher, compared to girls [19].
omen  (16–26 years old). Figure adapted from Garland et al. [18].
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Table  1
Scenarios and proposed approaches, for girls 9–14 years of age.
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We  ﬁrst consider the situation in girls less than 15 years of age,
here we can distinguish 4 scenarios:
In scenario A, revaccination, i.e., a girl has received two doses
f the bi- or quadrivalent HPV vaccine six months apart. Based on
mmunogenicity results, two doses of HPV vaccine, minimum six
onths apart should offer protection against the two, respectively,
our types in the vaccine, in girls between 9 and 14 years of age
20,21]. Consequently, in view of the immunogenicity data, WHO
hanged its previous recommendation of a 3-dose schedule to a
-dose schedule with a 6-month interval between doses for both
he bi- and quadrivalent HPV vaccines, in females younger than
5 years [22]. In most EU countries the vaccination schedule has
een reduced from three to two doses in the adolescent population. clinical trial is ongoing comparing safety and immunogenicity
f a 2-dose 9vHPV regimen in boys and girls 9 to 14 years of age
o a 3-dose schedule of 9vHPV in females 16 to 26 years of age
V503-010, ClinicalTrials.gov Identiﬁer: NCT01984697): availablerotection provided by the bi- and quadrivalent vaccines was ignored.
immunogenicity and safety data support the administration of a 2-
dose regimen of 9vHPV, where the second dose is administered 6 to
12 months (±1 month) following the ﬁrst dose, as an alternative to
the 3-dose regimen for girls and boys 9 to 14 years of age (data on
ﬁle). Based on these results, and using the same approach as that
previously accepted for licensure of a 2-dose regimen of 4vHPV,
efﬁcacy ﬁndings in young women who received the 3 dose regimen
of 9vHPV can be extended to girls and boys 9 to 14 years of age
who received the 2-dose (0, 6) or (0, 12) regimen including full
protection against the 5 additional types. For scenario A, to achieve
protection against the new types, the girl would therefore have to
be vaccinated with the 9vHPV vaccine, with 2 injections—6 to 12
months apart.In scenario B, a girl has received only two  doses of the bi- or
quadrivalent HPV vaccine two  months apart which is not the tim-
ing recommended by WHO  for a 2-dose vaccination schedule [22].
She may  therefore not be fully protected against the 2 or 4 HPV
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ypes [22]. This is likely to be remedied with an extra dose of 9vHPV
etween month 6 and month 12 – after the second dose of the origi-
al vaccine – to be fully protected against the original types she was
accinated against (two or four HPV types, respectively). However,
o achieve some extra protection against the 7 or 5 additional types
depending whether her initial doses were the bi- or the quadriva-
ent, respectively), she would need at least a second dose of 9vHPV
accine 6 to 12 months later, as there is no data supporting that
nly 1 dose of 9vHPV will offer full protection.
In scenario C, a girl has received only one dose of the bi-
r quadrivalent HPV vaccine. Currently there is no HPV vaccine
icensed for single dose administration and there is no robust
linical disease data supporting protection against the 2–4 HPV
ypes after one dose of bi- or quadrivalent vaccine, although some
vidence has been presented that a single dose of the bivalent
accine protects against HPV 16/18 infections for at least four
ears [23]. An extra dose of 9vHPV given 6 to 12 months after
he ﬁrst one should reasonably provide protection against the
–4 original types. However, to achieve extra protection against
he additional types, she would need at least a second dose of
vHPV vaccine 6 to 12 months after, as described in scenario
.
Scenario D represents a girl who has ﬁnished her bi- or quadriva-
ent HPV vaccination schedule with 3 doses. She is therefore fully
rotected against HPV types 16 and 18 (and HPV types 6 and 11
or the quadrivalent vaccine). To achieve extra protection against
he new types, the girl in this scenario should be vaccinated with
he 9vHPV vaccine at least with 2 doses given 6 to 12 months
part (if under the age of 15). As discussed above, this may  result
n a lower immune response (expressed as lower GMTs) to the
dditional HPV types, with an as yet unknown clinical signiﬁcance
24].
Table 1 summarizes, for each scenario, the vaccines, the interval
nd number of doses that should be considered, and the expected
rotection resulting from the extra doses.
In girls older than 15 years of age whose initial series was  given
efore 15 years of age and in women), as in scenario D revaccination
hould be considered; 3 doses 9vHPV vaccine, according to a 0,
 and 6 months schedule should be administered to provide full
rotection against the extra types in 9vHPV.
As previously mentioned, the scenarios described are not neces-
arily limited to girls, but may  also apply to boys. Proposed guidance
s based on available immunogenicity data supporting the admin-
stration of a 2-dose regimen of 9vHPV, where the second dose is
dministered 6 to 13 months (±1 month) following the ﬁrst dose,
s an alternative to the 3-dose regimen for girls and boys 9 to 14
ears of age. (Data on ﬁle; ongoing clinical trial V503-010, Clinical-
rials.gov Identiﬁer: NCT01984697).
We  are fully aware that there are limitations to the presented
cenarios, but so far no concrete data exist as vaccine trials with
he proposed schedules have not been performed. The results of
he 9vHPV vaccine study in females 12–26 years of age, previ-
usly completely vaccinated with 4vHPV, showed that the time
nterval between both series had no impact on the 9vHPV immuno-
enicity at month 7 [24]; the authors therefore do not expect
 time interval to have any impact, but age at the moment of
accine administration does. We  are also aware that what is pro-
osed in this paper should be regarded as valid for a transitional
eriod in time. In addition, it is not proposed that vaccines and
isits to existing programs (which would be major programmatic
hallenges) should be made. With the proposed scenarios the
uthors aim to address questions raised on an individual level
by a healthcare provider or vaccinee), rather than recommending
hat countries amend their HPV immunization program. Finally, we
eed to take into consideration that the durability of the response
nd the long-term efﬁcacy of any 2-dose HPV vaccine regimen
[e 34 (2016) 757–761
remains to be demonstrated, the impact on HPV, in particular
on CIN2+, needs to be measured, and safety to be further docu-
mented.
In conclusion, the introduction of the new 9vHPV vaccine offer-
ing a signiﬁcantly broader protection raises the question of what is
the most appropriate and practical way for completing a vaccina-
tion course already started. We  propose that the 9-valent vaccine
can be used to complete an incomplete vaccination regimen (sce-
nario B and C) or be added to a previous completed schedule
(scenario A and D) to extend protection. The number of doses
and timing depends on the doses already given, and the age of
the vaccinee. Finally, for those countries considering male vac-
cination, this position can also be applied to the vaccination of
boys.
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